Eris Lifesciences Limited
ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products.
What Eris files
- Investor Meet48
- Others48
- Important27
- Board Meeting18
- PPTs8
- Updates7
Eris Lifesciences secured a ₹64.40 Cr working capital loan from Axis Bank for short-term liabilities. This move ensures the company's aggregate debt level remains unchanged, maintaining stable leverage.
Eris Lifesciences reports robust growth: FY26 revenue 3,129 Cr, EBITDA 1,120 Cr. Strategic acquisitions (4,300+ Cr) and strong R&D drive expansion in Anti-Diabetes (6% share) & Insulins (16%). Sundae Gx Semaglutide launched strong. EU-GMP observations noted; minimal impact on existing business. FY27 revenue guided 18-20%.
Eris Lifesciences Limited has informed the Exchange regarding 'payment made of theinterest to the holders of Non-convertible Debentures'.
Eris Therapeutics' bank facilities affirmed/assigned IND AA/Stable/A1+ ratings. This reflects parent Eris Lifesciences' strong operating performance, with 9MFY26 EBITDA at ~INR 850 Cr, robust 35%+ margins, and successful strategic acquisitions like the INR 1,242 Cr Biocon Biologics deal. Net leverage improved to 2.2x, signaling financial stability.
Eris Lifesciences' Swiss Parenterals units faced HALMED observations on GMP compliance. While existing business sees minimal impact, expect delays in their EU-CDMO product pipeline. Remediation is underway.